These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3666843)

  • 21. [Effectiveness of treatment of patients with destructive forms of pulmonary tuberculosis with rifampicin and ethambutol].
    Mavrotskiĭ VV
    Klin Med (Mosk); 1974 Dec; 52(12):31-4. PubMed ID: 4444241
    [No Abstract]   [Full Text] [Related]  

  • 22. [Side effects of rifampicin used intermittently in treatment of chronic pulmonary tuberculosis].
    Zierski M; Kucharska A; Wislawska-Orlowska B
    Gruzlica; 1973 Nov; 41(11):1139-45. PubMed ID: 4765794
    [No Abstract]   [Full Text] [Related]  

  • 23. [Results of initial treatment of pulmonary tuberculosis using ethambutol, isonicotinic acid hydrazide and rifampicin].
    Kesztele V; Niederkofler J
    Wien Med Wochenschr; 1970 Jun; 120(25):473-5. PubMed ID: 5518004
    [No Abstract]   [Full Text] [Related]  

  • 24. [Rifampicin; its value and its limitations in tuberculosis, chronic or of severe onset, with or without associated ethambutol].
    Tricoire J; Marécaux L
    Rev Tuberc Pneumol (Paris); 1969 Mar; 33(2):226-41. PubMed ID: 5385585
    [No Abstract]   [Full Text] [Related]  

  • 25. [Treatment of pulmonary tuberculosis of native Black Africans a chemotherapeutic regime including rifampicin (apropos of 75 patients)].
    Ayad M; Hane A; Kane PA
    Dakar Med; 1980; 25(1):65-74. PubMed ID: 7460740
    [No Abstract]   [Full Text] [Related]  

  • 26. Intermittent chemotherapy of pulmonary tuberculosis using rifampicin and isoniazed for primary treatment: the influence of various factors on the frequency of side-effects.
    Eule H; Werner E; Winsel K; Iwainsky H
    Tubercle; 1974 Mar; 55(1):81-9. PubMed ID: 4470836
    [No Abstract]   [Full Text] [Related]  

  • 27. [Thrombocytopenia caused by rifampicin. Case report].
    Galietti F; Poy G; Passera R; Costa M
    Minerva Med; 1978 Jul; 69(34):2321-4. PubMed ID: 683584
    [No Abstract]   [Full Text] [Related]  

  • 28. [Epidemiology of jaundice in phthisiology department: responsibility of rifampicin].
    Oury M; Tuchais E; Tuchais M
    Rev Tuberc Pneumol (Paris); 1970; 34(3):415-22. PubMed ID: 5510436
    [No Abstract]   [Full Text] [Related]  

  • 29. Secondary amenorrhoea due to the use of rifampicin as an antimycobacterial agent.
    Swanton AG; Paterson-Brown S
    J Obstet Gynaecol; 2002 Mar; 22(2):227-8. PubMed ID: 12528712
    [No Abstract]   [Full Text] [Related]  

  • 30. Rifampicin-dependent antibodies in twice-weekly treated patients.
    Algeorge G; Rudescu D; Alexandrescu D
    Scand J Respir Dis Suppl; 1973; 84():98-101. PubMed ID: 4522081
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment of pulmonary tuberculosis with short course isoniazid-rifampicin regimen compared with standard regimen in ambulatory pediatric clinic.
    Trastotenojo MS; Wiroreno B; Santosa ; Soemantri AG; Hendarto T; Singgih Y
    Paediatr Indones; 1983; 23(11-12):240-9. PubMed ID: 6678404
    [No Abstract]   [Full Text] [Related]  

  • 32. Acute severe gastric intolerance to rifampicin.
    Gaude G
    J Postgrad Med; 1993; 39(2):113. PubMed ID: 8169860
    [No Abstract]   [Full Text] [Related]  

  • 33. The intermittent chemotherapy of tuberculosis with rifampicin regimens on ambulatory basis.
    Anastasatu C; Bungeteanu G; Sibila S
    Scand J Respir Dis Suppl; 1973; 84():136-9. PubMed ID: 4522068
    [No Abstract]   [Full Text] [Related]  

  • 34. [Study on the incidence of Australia antigen in a controlled experiment of treatment with rifampicin].
    Patricolo MR
    Arch Monaldi; 1974; 29(5-6):477-82. PubMed ID: 4467825
    [No Abstract]   [Full Text] [Related]  

  • 35. [Controlled comparison of daily and intermittent treatment regimens with rifampicin].
    Yamamoto K
    Bull Int Union Tuberc; 1974; 49(1):442-6. PubMed ID: 4619565
    [No Abstract]   [Full Text] [Related]  

  • 36. Further experience on glucose tolerance test during rifampicin therapy.
    Sharma TN; Agarwal KC; Gupta PR; Purohit SD; Sharma VK; Mathur BB
    J Assoc Physicians India; 1986 Feb; 34(2):131-3. PubMed ID: 3711003
    [No Abstract]   [Full Text] [Related]  

  • 37. Rifampicin--a leading drug in the therapy of tuberculosis not easily amenable to treatment.
    Tousek J
    Respiration; 1971; 28():Suppl:116-22. PubMed ID: 5150791
    [No Abstract]   [Full Text] [Related]  

  • 38. [Hepatic tolerance in man of rifampicin-isoniazid association].
    Toulet J; Plomteux G; Viteau JM; Abiven M; Bonfante N
    J Med Liban; 1971; 24(6):651-8. PubMed ID: 5146848
    [No Abstract]   [Full Text] [Related]  

  • 39. Rifampicin-induced renal toxicity during retreatment of patients with pulmonary tuberculosis.
    Rekha VV; Santha T; Jawahar MS
    J Assoc Physicians India; 2005 Sep; 53():811-3. PubMed ID: 16334628
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Letter: Acute renal failure due to rifampicin].
    Beruard M; Ducret F; Letacon J; Zech P
    Nouv Presse Med; 1974 Sep; 3(32):2025. PubMed ID: 4431709
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.